To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.

Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry

Gremese, Elisa;
2015-01-01

Abstract

To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.
2015
Antibodies
Monoclonal
Murine-Derived
Antirheumatic Agents
Dose-Response Relationship
Drug
Drug Monitoring
Drug Resistance
Immunosuppression
Lupus Erythematosus
Systemic
Middle Aged
Off-Label Use
Remission Induction
Rituximab
Severity of Illness Index
Treatment Outcome
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/85573
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 93
  • ???jsp.display-item.citation.isi??? 81
social impact